drugset / Trial / NCT04626973

Effects of Ezetimibe Combination Therapy for Patients With Atherosclerotic Cardiovascular Disease; Randomized Comparison of LDL-cholesterol Targeting <70 Versus <55mg/dL; Ez-PAVE Trial

NCT04626973

Completed 3048 enrolled Yonsei University
RandomizedFactorialOpen-labelTreatment

Summary

Although the clinical efficacy of LDL-cholesterol lowering therapy has been proven with strong evidences and emphasized, there are also growing concerns that intensive lipid-lowering therapy would be related to increased risk of adverse effects. In addition, statin potency from recent guidelines was set from the studies composed of mainly Caucasian population, although there is an inconsistency of statin effect according to ethnicity. Asian population showed more profound LDL reduction not only from high potent statin but also from moderate to low potent statin. Conventional strategies for lowering LDL-cholesterol focused on statins, therefore doubling of previously described dose of statin would be common way in patients with inadequate LDL-cholesterol levels. Adding ezetimibe will be an alternative strategy not only to lower LDL-cholesterol level and also to reduce the need of dosage of high-intensity statin to achieve sufficient LDL-cholesterol lowering effect. However, studies regarding the effect of intensive-targeting of lipid-lowering therapy and therapy regimens are lacking. Thus, on these basis, we sought to evaluate whether intensive-targeting of lipid-lowering therapy will have more prominent beneficial effect compared to conventional-targeting in patients with documented ASCVD with either an ezetimibe/statin combination therapy or a statin monotherapy.

Timeline

Start
2021-01-15
Primary completion
2025-09-24
Completion
2025-09-24

Drugs

EvaluationDrugModalityDoseRoute
Comparator Atorvastatin Small molecule 20 mg
Comparator Atorvastatin Small molecule 40 mg
Comparator Atorvastatin Small molecule 80 mg
Comparator Ezetimibe Unknown 10 mg
Comparator Rosuvastatin Small molecule 5 mg
Comparator Rosuvastatin Small molecule 10 mg
Comparator Rosuvastatin Small molecule 20 mg
Comparator Rosuvastatin Small molecule 40 mg
Comparator Rosuvastatin Small molecule 80 mg